. 2023 Sep 13;6(9):e2329583. doi: 10.1001/jamanetworkopen.2023.29583

Table 3. Results of Deterministic Sensitivity Analyses.

Strategy	Annual overdose rate per 1000 people^a	Remaining undiscounted LYs per person^b	Total discounted cost per person, $^b	Change in discounted cost per person, $^b	Remaining discounted QALYs per person^b	Change in remaining discounted QALYs per person^b	ICER ($/LY)^b	ICER ($/QALY)^b
Sensitivity analysis: 80% decreased pharmaceutical cost
No medication treatment strategy	7.77	20.54	241 070	NA	8.33	NA	NA	NA
Treatment with extended-release buprenorphine strategy	6.53	27.39	293 040	51 970	11.52	3.19	15 140	16 300
Treatment with transmucosal buprenorphine strategy	6.49	27.44	293 730	680	11.55	0.03	23 410	19 760
Sensitivity analysis: 191% increased retention
No medication treatment strategy	7.77	20.54	241 070	NA	8.33	NA	NA	NA
Treatment with transmucosal buprenorphine strategy	5.10	28.26	338 480	97 410	12.07	3.75	25 560	25 990
Treatment with extended-release buprenorphine strategy	4.27	28.57	358 280	19 800	12.28	0.20	118 610	97 840

Abbreviations: ICER, incremental cost-effectiveness ratio; LY, life-years; QALY, quality-adjusted life-years.

^{^a}

Calculated over the first 10 years of the simulation.

^{^b}

Costs and ICERs were rounded to nearest $10 and QALYs and LYs to nearest 0.01.